Author:
Zhao Yunyu,He Xinyuan,Ji Fanpu
Publisher
Springer Nature Singapore
Reference31 articles.
1. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453–64.
2. Ji F, Dang S, Cai Z, Xue H, Huang N, Liu L, Zhang S, Guo Y, Jia X, Wang Y, Li Z, Deng H. Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection. Zhonghua Gan Zang Bing Za Zhi. 2015;23:647–52.
3. Ji F, Zhang S, Deng H, Li Z. Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis. J Hepatol. 2013;58:1262–4.
4. Ji F, Li J, Liu L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. J Gastroenterol Hepatol. 2021;36:767–74.
5. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218.